% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • rehdvm2004 rehdvm2004 Apr 13, 2014 7:08 AM Flag

    Phase III Clinical Trial . . .

    will succeed because the patient enrollment population will be selected from patients that have NTM detected for the first time. Not patients enrolled after failure of the currently non-effective 6 months regimen. If NTM patients are enrolled when they first are diagnosed with three positive sputum samples, the damage to the lungs and the build-up of biofilm, infected macrophages and any associated pathology is averted. Treating this patient population should get a high order of cures and positive results (zero NTM detected and/or statistically significant NTM population reduction) well within the 84 day period.

    INSM does not want to treat more patients where Arikace rescues from failed treatments. They want to treat naïve patients that have low levels of infection, minimal biofilm/mucous build-up and minimal airway damage so the Arikace can fill the conducting airways. That will produce the cures.

    I think that might be the INSM/Dr. Olivier approach. We shall see.


    Sentiment: Buy

9.21-0.39(-4.06%)12:07 PMEDT